Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15669092 | 0.78 | HDAC1 (0.47) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL15668237 | 0.77 | HDAC1 (0.56) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL830717 | 0.70 | HDAC1 (0.77) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL830716 | 0.70 | HDAC1 (0.77) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL8291156 | 0.69 | HDAC1 (0.56) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL3370685 | 0.69 | HDAC1 (0.52) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL8242516 | 0.68 | HDAC1 (0.57) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL8290498 | 0.68 | HDAC1 (0.57) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL8318780 | 0.68 | HDAC1 (0.63) | HDAC1HDAC6HDAC8HDAC3HDAC4 | |
| SCHEMBL8320107 | 0.67 | HDAC1 (0.66) | HDAC1HDAC6HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | claimed |
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | claimed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | claimed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | claimed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | claimed |
| EP-1937650-A1 | HETEROCYCLIC COMPOUNDS | S*Bio Pte Ltd (SG) | 2008-07-02 | — | — | EP | claimed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | claimed |
| EP-2131840-B1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| EP-1937650-A1 | HETEROCYCLIC COMPOUNDS | S*Bio Pte Ltd (SG) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC6 10/4885HDAC8 4/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | HDAC1 47/4885HDAC6 10/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.